AMIX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AM

Mkt Cap

$6.1M

Volume

32.22K

Next Earnings

November 11th

Chart Earnings News About Insider Filings

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq RulesAutonomix Medical announced a warrant inducement agreement with an investor to exercise outstanding July 2026 Warrants for 857,462 shares at $5.75 per share, generating approximately $4.9 million in gross proceeds. In exchange, the company issued new Series E-1 and E-2 warrants to purchase 535,913 shares each at $6.25 per share. The transaction is expected to close on August 26, 2026.GlobeNewswire Inc. · Aug 25, 2026

Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical StudyAutonomix Medical announced positive preclinical study results showing its neural sensing platform can detect, localize, and confirm changes in renal neural activity. The technology enables physiological feedback during renal denervation procedures, potentially addressing current limitations where physicians rely on anatomical landmarks rather than direct neural information. The company plans further preclinical and clinical studies to evaluate physiology-guided renal denervation applications.GlobeNewswire Inc. · Jul 24, 2026

Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq RulesAutonomix Medical announced a warrant inducement agreement where an investor will exercise outstanding warrants to purchase 428,731 shares at $6.00 per share, generating approximately $2.6 million in gross proceeds. In return, the company will issue new Series D-1 and D-2 warrants with a $5.75 exercise price. The transaction is expected to close on or about July 15, 2026.GlobeNewswire Inc. · Jul 14, 2026

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific ConferenceAutonomix Medical will present two podium sessions at the Transcatheter Cardiovascular Therapeutics Annual Scientific Conference, highlighting their first-in-human clinical study on transvascular energy delivery for pancreatic cancer pain mitigation.GlobeNewswire Inc. · Oct 24, 2025

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAutonomix Medical, a medical device company developing innovative nerve-targeted treatment technologies, will present at the Webull Financial Corporate Connect Webinar Series on August 21, 2025, discussing their microchip-based intravascular nerve sensing platform.GlobeNewswire Inc. · Aug 15, 2025

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Autonomix Medical, Inc. (NASDAQ: AMIX) announced the grant of a stock option to a new non-executive employee as an inducement to their employment. The option has a 10-year term and vests over four years, subject to continued service.GlobeNewswire Inc. · Mar 21, 2025

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based TechnologyAutonomix Medical, Inc. has been granted a U.S. patent for its technology that aims to treat cancerous tumors and cancer-related pain. The company's preclinical studies have shown promising results in reducing metastases and tumor mass, and it plans to further explore the potential of its technology to slow pancreatic cancer growth and metastasis.GlobeNewswire Inc. · Dec 30, 2024

A.M.AUTONOMY Showcases MAP-TORCH for 3D Construction Digitalization at KINTEXA.M.AUTONOMY will showcase its 'MAP-TORCH' solution, which digitizes construction sites into 3D, at the Smart Construction Expo in South Korea. The solution can also integrate sensors for detecting hazardous gases and radiation, aiding in accident prevention in nuclear facilities.GlobeNewswire Inc. · Nov 18, 2024

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate UpdateAutonomix Medical, Inc. reported positive results from its ongoing clinical trial for the treatment of pancreatic cancer pain, with 100% of lead-in patients achieving zero opioid use and significant pain reduction. The company is focused on advancing its proprietary nerve-targeting technology and expects to complete the trial by the end of 2024.GlobeNewswire Inc. · Nov 11, 2024

Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - BenzingaMatch Group shares jumped 8% in pre-market trading after Starboard Value took a stake of over 6.5% in the company and is advocating for a potential sale. Several other stocks also saw significant pre-market movement.Benzinga · Jul 16, 2024

AM

AMIXAutonomix Medical, Inc. Common Stock

AMIX

Pay with—

Available Balance0.00

Your PositionYou don't own any AMIX yet.

Related Tickers

Earnings